500 patients67,039 observations150 daysLIVE

Patient P-03031

Synthetic patientONX-7 · Day 138 · 55–64 · M · baseline S16Steering view · 3DOpen companion preview
Therapy response
Declining
Tolerance
Deteriorating
GI state
Stable
Inflammatory state
Stable
Nutritional resilience
Declining
Discontinuation risk
47%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 ONX-7 startedBaseline state S16
  2. Day 102 CR-01 recommendedClinician Review CR-01
  3. Day 103 Trajectory diverged from predictionObserved response fell below the model's expected path.
  4. Day 103 Patient acceptedStarted CR-01 in the companion
  5. Day 108 Deterioration detected before clinical escalationClinician Review CR-01

What changed?

Trajectory began diverging from predicted response on Day 103.

Primary contributors, last 14 days
  • Toxicity+9
  • Treatment adherence-8
  • Nutritional resilience-4
  • Inflammatory activity+3
  • GI instability+2

What helped?

  • Clinician Review CR-01Day 102
    Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
52%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 83% showed improvement
  • median effect visible after 8 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Energy level
Daily log
3.1/10
worsening · -0.9 vs previous 14 d
Stress level
Daily log
7.1/10
worsening · +0.5 vs previous 14 d
Pessimism score
Daily log
5.5/10
worsening · +0.9 vs previous 14 d
Sleep quality
Wearable
21.8/100
worsening · -4.5 vs previous 14 d
Libido
Daily log
2.1/10
worsening · -1.0 vs previous 14 d
HRV
Wearable
22 ms
worsening · -2.3 vs previous 14 d
Toxicity
Blood
43.5/100
worsening · +16.5 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards failing · 36 from the failing basin, 51 from restoration.

Would help
  • GI-04 GI Support Protocol
    74% improved among 34 similar · onset 8 d · confidence 48%
  • DT-01 Dosing / Timing Recommendation
    82% improved among 11 similar · onset 5 d · confidence 52%
  • SC-12 Supportive Compound
    89% improved among 9 similar · onset 6 d · confidence 52%
  • More protein
    GI -3.7 next day on high-intake days · n 14
Would not help
  • AD-05 Adherence Support
    only 27% improved among 11 similar
  • Keep histamine low
    GI +3.4 next day on high-intake days · n 26
  • Keep lactose low
    GI +1.9 next day on high-intake days · n 24
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Protein
    -3.7supporter · 95%
  • Histamine load
    +3.4detractor · 95%
  • Lactose
    +1.9detractor · 72%
  • Alcohol
    -0.6no signal · 20%
  • Caffeine
    -0.3no signal · 15%
  • Dietary fat load
    0no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Inflammatory signalling 85
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 50
    • WearableHRV 22 ms, trending down
  • Mucosal barrier integrity 80
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • MicrobiomeAkkermansia low → thinner mucus layer
    • Daily logGI symptom score 48 and rising
  • Butyrate / short-chain fatty acid production 45
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Drug metabolism and exposure 20
    • BloodToxicity index 44
  • Autonomic recovery 20
    • WearableShort sleep window
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Normal metabolizer
    Expected exposure
  • MTHFR C677T
    Reduced folate turnover
Microbiome
Shannon diversity 2.6 · butyrate capacity 46/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisHigh
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
21 ms
Sleep
6.4 h
Steps
4,955
Resting HR
67 bpm
Daily log: GI score 48, nutritional resilience 45, adherence 74.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • Keep the current walking rhythm
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0346348%S11GI-04no change55
P-0322544%S19GI-04improved50
P-0338244%S01GI-04improved56
P-0302141%S1557
P-0321841%S2056
P-0337941%S12GI-04improved51
P-0328040%S1357
P-0329239%S1462
P-0312037%S1461
P-0316637%S20CR-01improved62
P-0319137%S19GI-04improved51
P-0320037%S1659